JP2013516393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516393A5 JP2013516393A5 JP2012546344A JP2012546344A JP2013516393A5 JP 2013516393 A5 JP2013516393 A5 JP 2013516393A5 JP 2012546344 A JP2012546344 A JP 2012546344A JP 2012546344 A JP2012546344 A JP 2012546344A JP 2013516393 A5 JP2013516393 A5 JP 2013516393A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- lower alkyl
- optionally substituted
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940041181 antineoplastic drug Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 53
- 125000005843 halogen group Chemical group 0.000 description 42
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 37
- 125000003545 alkoxy group Chemical group 0.000 description 36
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 32
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- -1 cyan Chemical group 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XUIRHRWOJCYEDJ-UHFFFAOYSA-N 7-fluoroquinoline Chemical compound C1=CC=NC2=CC(F)=CC=C21 XUIRHRWOJCYEDJ-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009076321 | 2009-12-31 | ||
| CNPCT/CN2009/076321 | 2009-12-31 | ||
| PCT/CN2010/080499 WO2011079804A1 (en) | 2009-12-31 | 2010-12-30 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013122502A Division JP2013209418A (ja) | 2009-12-31 | 2013-06-11 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516393A JP2013516393A (ja) | 2013-05-13 |
| JP2013516393A5 true JP2013516393A5 (enrdf_load_stackoverflow) | 2013-08-01 |
| JP5337313B2 JP5337313B2 (ja) | 2013-11-06 |
Family
ID=44226181
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546344A Active JP5337313B2 (ja) | 2009-12-31 | 2010-12-30 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2013122502A Pending JP2013209418A (ja) | 2009-12-31 | 2013-06-11 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2016074893A Active JP6194046B2 (ja) | 2009-12-31 | 2016-04-04 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2017155493A Active JP6486999B2 (ja) | 2009-12-31 | 2017-08-10 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2019028197A Active JP6647434B2 (ja) | 2009-12-31 | 2019-02-20 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013122502A Pending JP2013209418A (ja) | 2009-12-31 | 2013-06-11 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2016074893A Active JP6194046B2 (ja) | 2009-12-31 | 2016-04-04 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2017155493A Active JP6486999B2 (ja) | 2009-12-31 | 2017-08-10 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2019028197A Active JP6647434B2 (ja) | 2009-12-31 | 2019-02-20 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
Country Status (38)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54217B1 (sr) * | 2009-12-31 | 2015-12-31 | Hutchison Medipharma Limited | Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja |
| ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
| CN102516046A (zh) * | 2011-11-22 | 2012-06-27 | 太仓市运通化工厂 | 一种2-溴丙醛的合成方法 |
| MX359888B (es) * | 2012-03-30 | 2018-10-15 | Rhizen Pharmaceuticals Sa | Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas. |
| CA2776178A1 (en) | 2012-04-05 | 2013-10-05 | Hydro-Quebec | Ionic compounds |
| KR101745741B1 (ko) | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
| CN104903320B (zh) * | 2013-01-11 | 2018-11-13 | 富士胶片株式会社 | 含氮杂环化合物或其盐 |
| RU2656597C2 (ru) | 2013-03-06 | 2018-06-06 | Астразенека Аб | Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста |
| CN103265468A (zh) * | 2013-06-17 | 2013-08-28 | 连云港盛和生物科技有限公司 | 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法 |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| DK3053923T3 (en) * | 2013-09-30 | 2018-07-23 | Korea Res Inst Chemical Tech | TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS |
| ES2654931T3 (es) * | 2013-12-26 | 2018-02-15 | Ignyta, Inc. | Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos |
| JP2016048495A (ja) * | 2014-08-28 | 2016-04-07 | 京セラ株式会社 | 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法 |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3398951B1 (en) * | 2015-12-31 | 2021-04-07 | Shanghai Pharmaceuticals Holding Co., Ltd. | Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications |
| GB201616116D0 (en) | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| KR20180092096A (ko) | 2017-02-08 | 2018-08-17 | 에이비온 주식회사 | 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법 |
| KR102880704B1 (ko) | 2017-03-01 | 2025-11-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN108570053A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元并六元杂环化合物、制备方法、中间体、组合和应用 |
| KR101924801B1 (ko) | 2017-08-16 | 2018-12-04 | 한국원자력의학원 | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| TWI833800B (zh) | 2018-09-11 | 2024-03-01 | 瑞典商阿斯特捷利康公司 | 用於製造3-[(1S)-1-咪唑并[1,2-a]吡啶-6-基乙基]-5-(1-甲基吡唑-4-基)三唑并[4,5-b]吡嗪的改進方法及其多晶型形式 |
| AU2019346464A1 (en) | 2018-09-25 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
| JP2022510501A (ja) * | 2018-10-30 | 2022-01-26 | リペア セラピューティクス インコーポレイテッド | 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法 |
| CA3122575A1 (en) | 2018-12-14 | 2020-06-18 | Beta Pharma, Inc. | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof |
| KR20210104071A (ko) | 2018-12-17 | 2021-08-24 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 표적 투약 |
| KR20220004024A (ko) | 2019-03-22 | 2022-01-11 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 약제학적 조성물 |
| AU2020317381A1 (en) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc. | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
| CN115362162A (zh) * | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| WO2021229605A1 (en) * | 2020-05-14 | 2021-11-18 | Dr. Reddy's Laboratories Limited | Process for preparation of savolitinib and its intermediates |
| US20240026401A1 (en) * | 2020-09-28 | 2024-01-25 | Codexis, Inc. | Engineered biocatalysts and methods for synthesizing chiral amines |
| WO2022133046A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR102659095B1 (ko) | 2021-01-08 | 2024-04-19 | 에이비온 주식회사 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
| CN113278019A (zh) * | 2021-05-31 | 2021-08-20 | 河南偶联生物科技有限公司 | 一种咪唑并[1,2-a]吡啶类化合物的合成方法 |
| KR20250003894A (ko) * | 2022-04-20 | 2025-01-07 | 엔그레일 테라퓨틱스, 인크. | Gabaa 수용체 조절제 염, 입자, 및 이의 용도 |
| EP4551226A1 (en) | 2022-07-08 | 2025-05-14 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| AU2023312919A1 (en) * | 2022-07-29 | 2025-03-06 | Baylor College Of Medicine | Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same |
| CN115611802B (zh) * | 2022-12-02 | 2023-03-14 | 北京迪泰医药科技有限公司 | 一种3-乙酰基-2-氯吡啶的合成方法 |
| WO2024148089A1 (en) * | 2023-01-04 | 2024-07-11 | Blueprint Medicines Corporation | Cdk2 inhibitors |
| GB202300923D0 (en) | 2023-01-20 | 2023-03-08 | Macfarlan Smith Ltd | Novel polymorphic forms of savolitinib |
| WO2024263860A1 (en) * | 2023-06-22 | 2024-12-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP1082324A4 (en) * | 1998-05-26 | 2002-01-02 | Merck & Co Inc | IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS |
| JP2000119250A (ja) * | 1998-08-11 | 2000-04-25 | Takeda Chem Ind Ltd | 環状アミド化合物、その製造法、中間体及び除草剤 |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| JP2007516180A (ja) * | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| WO2005028480A2 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| KR20070053237A (ko) | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 피롤로-피리딘 키나제 조절제 |
| MX2007002050A (es) | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
| HRP20100477T1 (hr) | 2005-02-16 | 2010-10-31 | Astrazeneca Ab | Kemijski spojevi |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| BRPI0619252A2 (pt) | 2005-11-30 | 2011-09-20 | Vertex Pharma | inibidores de c-met e seus usos |
| US8030305B2 (en) * | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| CA2651979A1 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| JP2010500365A (ja) | 2006-08-07 | 2010-01-07 | インサイト・コーポレイション | キナーゼ阻害剤としてのトリアゾロトリアジン |
| WO2008036272A1 (en) | 2006-09-18 | 2008-03-27 | Vertex Pharmaceuticals Incorporated | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| PT2084162E (pt) | 2006-10-23 | 2012-10-09 | Sgx Pharmaceuticals Inc | Triazoles bicíclicos como moduladores de proteína quinase |
| DK2081937T3 (da) * | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Triazolopyridazin-proteinkinasemodulatorer |
| MX2009005144A (es) | 2006-11-22 | 2009-05-27 | Incyte Corp | Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa. |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| JP2010524858A (ja) | 2007-04-10 | 2010-07-22 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 縮合環複素環キナーゼ調節因子 |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| WO2009105782A1 (en) * | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
| EP2265614A1 (en) | 2008-02-28 | 2010-12-29 | Novartis AG | Imidazo [1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| JP2011520986A (ja) | 2008-05-22 | 2011-07-21 | アムジエン・インコーポレーテツド | タンパク質キナーゼ阻害薬としての複素環類 |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| JP5781510B2 (ja) * | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| IN2012DN01453A (enrdf_load_stackoverflow) * | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| RS54217B1 (sr) * | 2009-12-31 | 2015-12-31 | Hutchison Medipharma Limited | Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja |
| ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
-
2010
- 2010-12-30 RS RS20150584A patent/RS54217B1/sr unknown
- 2010-12-30 MX MX2012007756A patent/MX336996B/es active IP Right Grant
- 2010-12-30 EP EP15170608.2A patent/EP2966075B1/en active Active
- 2010-12-30 SI SI201032046T patent/SI3511330T1/sl unknown
- 2010-12-30 CN CN201080065014.1A patent/CN102906092B/zh active Active
- 2010-12-30 CA CA2785749A patent/CA2785749C/en active Active
- 2010-12-30 DK DK19151824.0T patent/DK3511330T3/da active
- 2010-12-30 ME MEP-2015-150A patent/ME02211B/me unknown
- 2010-12-30 ES ES19151824T patent/ES2840454T3/es active Active
- 2010-12-30 EA EA201200951A patent/EA025466B1/ru not_active IP Right Cessation
- 2010-12-30 KR KR1020177022937A patent/KR101905350B1/ko active Active
- 2010-12-30 KR KR1020147010967A patent/KR101771299B1/ko active Active
- 2010-12-30 HU HUE19151824A patent/HUE052828T2/hu unknown
- 2010-12-30 PL PL19151824T patent/PL3511330T3/pl unknown
- 2010-12-30 CU CU20120101A patent/CU24167B1/es active IP Right Grant
- 2010-12-30 WO PCT/CN2010/080499 patent/WO2011079804A1/en not_active Ceased
- 2010-12-30 EA EA201691461A patent/EA030141B1/ru not_active IP Right Cessation
- 2010-12-30 BR BR112012016129-6A patent/BR112012016129B1/pt active IP Right Grant
- 2010-12-30 JP JP2012546344A patent/JP5337313B2/ja active Active
- 2010-12-30 HR HRP20221090TT patent/HRP20221090T1/hr unknown
- 2010-12-30 HU HUE13198224A patent/HUE025504T2/en unknown
- 2010-12-30 EP EP19151824.0A patent/EP3511330B1/en active Active
- 2010-12-30 LT LTEP20199091.8T patent/LT3795573T/lt unknown
- 2010-12-30 MX MX2016001733A patent/MX386852B/es unknown
- 2010-12-30 RS RS20220854A patent/RS63612B1/sr unknown
- 2010-12-30 SM SM20200693T patent/SMT202000693T1/it unknown
- 2010-12-30 PE PE2016000292A patent/PE20160588A1/es unknown
- 2010-12-30 PE PE2020001800A patent/PE20211094A1/es unknown
- 2010-12-30 SI SI201031021T patent/SI2719699T1/sl unknown
- 2010-12-30 ES ES15170608T patent/ES2726152T3/es active Active
- 2010-12-30 MY MYPI2012002974A patent/MY179933A/en unknown
- 2010-12-30 CN CN201610432059.7A patent/CN106432225B/zh active Active
- 2010-12-30 EP EP10840591.1A patent/EP2519524A4/en not_active Withdrawn
- 2010-12-30 ES ES13198224.1T patent/ES2546635T3/es active Active
- 2010-12-30 PE PE2012000903A patent/PE20130375A1/es not_active Application Discontinuation
- 2010-12-30 PT PT131982241T patent/PT2719699E/pt unknown
- 2010-12-30 US US13/501,222 patent/US8987269B2/en active Active
- 2010-12-30 PT PT191518240T patent/PT3511330T/pt unknown
- 2010-12-30 EP EP20199091.8A patent/EP3795573B1/en active Active
- 2010-12-30 PT PT201990918T patent/PT3795573T/pt unknown
- 2010-12-30 NZ NZ601128A patent/NZ601128A/en unknown
- 2010-12-30 ES ES20199091T patent/ES2927146T3/es active Active
- 2010-12-30 DK DK20199091.8T patent/DK3795573T3/da active
- 2010-12-30 UA UAA201208929A patent/UA107822C2/ru unknown
- 2010-12-30 HU HUE20199091A patent/HUE059696T2/hu unknown
- 2010-12-30 SG SG2012044830A patent/SG181781A1/en unknown
- 2010-12-30 SM SM20220371T patent/SMT202200371T1/it unknown
- 2010-12-30 EP EP13198224.1A patent/EP2719699B1/en active Active
- 2010-12-30 AU AU2010338712A patent/AU2010338712B2/en active Active
- 2010-12-30 KR KR1020127019509A patent/KR101434766B1/ko active Active
- 2010-12-30 RS RS20201567A patent/RS61281B1/sr unknown
- 2010-12-30 DK DK13198224.1T patent/DK2719699T3/en active
- 2010-12-30 PL PL20199091.8T patent/PL3795573T3/pl unknown
- 2010-12-30 PH PH1/2012/501355A patent/PH12012501355A1/en unknown
- 2010-12-30 PL PL13198224T patent/PL2719699T3/pl unknown
- 2010-12-30 CN CN201610437304.3A patent/CN106117248B/zh active Active
-
2012
- 2012-04-10 US US13/501,224 patent/US8507487B2/en active Active
- 2012-06-14 IL IL220433A patent/IL220433B/en active IP Right Grant
- 2012-06-26 CL CL2012001752A patent/CL2012001752A1/es unknown
- 2012-06-28 GT GT201200220A patent/GT201200220A/es unknown
- 2012-06-29 DO DO2012000188A patent/DOP2012000188A/es unknown
- 2012-06-29 CO CO12109937A patent/CO6612235A2/es not_active Application Discontinuation
- 2012-06-29 NI NI201200118A patent/NI201200118A/es unknown
- 2012-06-29 EC EC2012012011A patent/ECSP12012011A/es unknown
- 2012-07-30 ZA ZA2012/05730A patent/ZA201205730B/en unknown
-
2013
- 2013-06-11 JP JP2013122502A patent/JP2013209418A/ja active Pending
-
2015
- 2015-01-21 US US14/601,674 patent/US20150368271A1/en not_active Abandoned
- 2015-06-23 AU AU2015203480A patent/AU2015203480B2/en active Active
- 2015-07-16 IL IL239997A patent/IL239997A/en active IP Right Grant
- 2015-09-08 HR HRP20150952TT patent/HRP20150952T1/hr unknown
- 2015-09-09 SM SM201500213T patent/SMT201500213B/xx unknown
- 2015-09-17 CY CY20151100816T patent/CY1118250T1/el unknown
-
2016
- 2016-04-04 JP JP2016074893A patent/JP6194046B2/ja active Active
- 2016-10-14 US US15/293,722 patent/US9956218B2/en active Active
-
2017
- 2017-08-10 JP JP2017155493A patent/JP6486999B2/ja active Active
-
2018
- 2018-04-04 US US15/945,324 patent/US10512645B2/en active Active
-
2019
- 2019-02-20 JP JP2019028197A patent/JP6647434B2/ja active Active
- 2019-11-08 US US16/678,091 patent/US10946014B2/en active Active
-
2020
- 2020-12-17 HR HRP20202017TT patent/HRP20202017T1/hr unknown
- 2020-12-21 CY CY20201101206T patent/CY1123777T1/el unknown
-
2021
- 2021-02-03 US US17/248,688 patent/US11896592B2/en active Active
-
2023
- 2023-12-13 US US18/538,151 patent/US20240139182A1/en not_active Abandoned
-
2024
- 2024-05-28 US US18/676,172 patent/US20250099462A1/en active Pending